What is BioCryst Pharmaceuticals, Inc.'s Shariah compliance score?

BioCryst Pharmaceuticals, Inc. (BCRX) has a Shariah compliance score of 69/100 (Grade: B, Acceptable) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does BioCryst Pharmaceuticals, Inc. pass AAOIFI screening?

BioCryst Pharmaceuticals, Inc. (BCRX) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (BCRX: 15.8%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 6,200+ stocks at halalscreener.app.

How much purification is needed for BioCryst Pharmaceuticals, Inc. stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for BioCryst Pharmaceuticals, Inc. (BCRX) using the latest financial data.

Where can I screen BioCryst Pharmaceuticals, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for BioCryst Pharmaceuticals, Inc. (BCRX) and 5,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about BCRX's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

BCRX: Is BioCryst Pharmaceuticals, Inc. Halal?

BioCryst Pharmaceuticals, Inc.

NASDAQHealthcareUS

$9.82

-0.51%

Market Cap: 2.5B

Compliance Status

Halal

Screened on Aug 30, 2026 · AAOIFI Standard 21

Acceptable

69Score

Is BioCryst Pharmaceuticals, Inc. (BCRX) halal? Halal. Based on AAOIFI screening, BioCryst Pharmaceuticals, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 69/100 (Grade: B).

Quote this verdict

HalalScreener rates BioCryst Pharmaceuticals, Inc. (BCRX) Halal, 69/100, grade B under AAOIFI Standard 21, screened Aug 30, 2026. Source: https://halalscreener.app/en/stock/BCRX

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Within the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

15.8% of 30.0% limit

What this means for you

You can own BCRX

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purification amount is Pro

We have screened BCRX's prohibited income, but the exact share you would need to purify is part of Pro.

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Aug 30, 2026

Compliance History

Halalnow
since Jun 2026
Not Halal
until the change above
Halal
until the change above
Not Halal
until the change above

Tracked since Jun 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track BCRX and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is BioCryst Pharmaceuticals, Inc. (BCRX) halal to invest in?

Based on AAOIFI Standard 21 screening, BioCryst Pharmaceuticals, Inc. (BCRX) is rated Halal with a compliance grade of B (Acceptable). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did BioCryst Pharmaceuticals, Inc. get a B compliance rating?

BioCryst Pharmaceuticals, Inc. (BCRX) received a grade of B (Acceptable) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 15.8% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change BioCryst Pharmaceuticals, Inc.'s Shariah verdict?

BioCryst Pharmaceuticals, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is BioCryst Pharmaceuticals, Inc. re-screened for Shariah compliance?

BioCryst Pharmaceuticals, Inc. (BCRX) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Aug 30, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.